Enrique Grande, One Oncology Madrid Program Director at Quironsalud, shared on X:
” New meta-analysis confirming the benefit of perioperative immune-based strategies in cisplatin-eligible MIBC (NIAGARA + KEYNOTE-B15).
Meaningful EFS and OS gains – but the two regimens are not interchangeable.
Patient selection matters.”
Title: Perioperative immune-based treatment for cisplatin-eligible muscle-invasive bladder cancer: a meta-analysis of randomized controlled trials
Authors: Veronica Mollica, Matteo Rosellini, Patrizia Giannatempo, Shilpa Gupta, Enrique Grande, Alessandro Rizzo, Costantino Ricci, Pietro Piazza, Roberto Contieri, Arrigo Cattabriga, Riccardo Schiavina, Matteo Santoni, Francesco Massari
You can also read: Advanced Bladder Cancer: How Is First-Line Treatment Changing?
